Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Tecentriq 840 mg/14 mL solution for intravenous infusion Images

Generic Name: atezolizumab

This medication has been identified as Tecentriq 840 mg/14 mL solution for intravenous infusion. It is supplied by Genentech, Inc.

Tecentriq is used in the treatment of Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Alveolar Soft Part Sarcoma; Hepatocellular Carcinoma; Melanoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Tecentriq 840 mg/14 mL solution for intravenous infusion is not a controlled substance under the Controlled Substances Act (CSA).

Images

Tecentriq (Atezolizumab [ a-te-zoe-liz-ue-mab ])-medicine-840 mg/14 mL solution for intravenous infusion

Tecentriq
Generic Name: atezolizumab [ a-te-zoe-liz-ue-mab ]
Imprint: medicine
Strength: 840 mg/14 mL solution for intravenous infusion
Color: N/A
Size: N/A
Shape: N/A
Availability: Prescription only
Drug Class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Pregnancy Category: N/A
CSA Schedule: Not a controlled drug
Labeler / Supplier: N/A
National Drug Code (NDC): 50242-0918
Inactive Ingredients:
Latest News
Related Drugs